

UNCLASSIFIED

EXECUTIVE SUMMARY

DACH-SPR
15 SEP 21

(U) FRAGO 5 to HQDA EXORD 225 (COVID-19 SS OPNS) Summary. (U) (DACH-SPR) This document provides summary of 141712ZSEP21 mandatory COVID-19 DA guidance to COMPO 1/2/3 Service Members (SMs). Please see FRAGO paragraph and line number locations in parentheses (#X#X#).

1. Applicability. FRAGO 5 does not address Federal civilian or contractor employees. Per G3 during this week's ASA M&RA update, possible FRAGOs 6-7 will address these employees. Mandatory vaccination operations will occur in two phases: PH1 Vaccinate; PH2 Remove Refusing SMs (unofficial phase names). PH1 begins immediately; PH2 on order (3B3A1 & 3D8B2). Pfizer is the only FDA approved vaccine, though SMs may voluntarily continue to receive other brand vaccines (3D8A). Vaccination suspense: COMPO 1: 15 DEC 21, COMPO 2/3: 30 JUN 22 (3D14).

2. Authority. Orders to receive mandatory vaccine are lawful (3D8B2). SMs requesting exemption are not required to receive vaccine pending the exemption request final decision (3D8B1).

3. Refusal. Commanders, Senior NCOs, and Enlisted SMs serving in CSL/ key billet/ nominative positions, or selected for and waiting to assume those positions who refuse the vaccine, and not pending exemption request final decision, will be relieved (3D8B1A-B). Commanders will initiate GOMORs for all SMs refusing the vaccine who do not have a pending request (3D8B1D). SMs who refuse vaccination will be flagged unless pending an exemption (3D8B1E). There will be no involuntary immunizations (Note: AR 600-20 authorizes involuntary immunizations) (3D8B4). Process when SM declines immunization: a) commander counseling, b) SM mandated to watch CDC video, c) commander re-orders vaccination, d) if SM re-declines, commander initiates UCMJ (3D8B5A).

4. Religious accommodation (RA). SECARMY grants ASA M&RA vaccine RA request appeal authority (3D8B6B). RA process mirrors AR 600-20 for COMPO 1 & 3. COMPO 2 (ARNG) is not required to submit medical provider's memo (3D8B8). Annex XX, FRAGO 5 documents refusal and RA pathways.

CH (LTC) Bill Martin/DACH-SPR/571-256-8770
william.a.martin2.mil@mail.mil

APPROVED BY: CH (COL) Huey

UNCLASSIFIED